Spotlight on China

The 20th annual BIO International Convention is wrapping up in Chicago. Experts and leaders from leading global biotechnology, biologics and investment companies gathered together to discuss the opportunities and challenges in the biologics industry. A large China Food and Drug Administration (CFDA) delegation led by Deputy Commissioner Bian Zhenjia participated in a half-day session dedicated to developing a world-class therapeutic biologics industry in China.

There has been a shift in recent years in the usage of large-molecule biologics in the global drug market. The market share of biologics has grown from 13 percent in 2006 to 17 percent in 2010. Despite this trend, the market share of biologics in China’s drug market has been around 5 percent over the past five years, prompting the need by industry and regulators to accelerate the sector’s development. In response, BIO and the R&D Based Pharmaceutical Association Committee (RDPAC) have produced a White Paper titled Building a World-Class Innovative Therapeutic Biologics Industry in China.

Business and Investments  |  Email This Post  |  Printer Friendly
Tags: , , , ,

One Response to Spotlight on China

  1. Mike says:

    Biologics are comparatively more complex than chemical ones, and it is more challenging to ensure their quality and safety. The development of the biologics industry plays a key role in the development of China’s pharmaceutical industry and economy. The government should clarify the definition of biologics and biosimilars and establish clear regulatory pathways in particular for biosimilars with requirement in line with international standards to ensure the safety and quality of biologics

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>